AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom. Due to the rising use of antithrombotic medications and the complexity of specific clinical cases requiring such therapies, bleeding remains the primary concern among patients using antithrombotics. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. In recent years, anticoagulant and antiplatelet use have increased over the past years for the prevention and treatment of several cardiovascular conditions. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006 and Personalis, Inc. Low titers of anti-ANDEXXA antibodies were observed in 26/145 healthy subjects (17) 6 (9/145) were first observed at Day 30 with 20 subjects (14. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. Using an electrochemiluminescence (ECL)-based assay, 145 ANDEXXA-treated healthy subjects were tested for antibodies to ANDEXXA as well as antibodies cross-reacting with Factor X (FX) and FXa. Its marketed products also comprise Synagis for respiratory syncytial virus Fluenz Tetra/FluMist Quadrivalent for Influenza and Vaxzevria and Evusheld for covid-19. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
0 Comments
Leave a Reply. |